Results 221 to 230 of about 3,173,890 (267)

Comparative study of several hypolipidemic agents related to clofibrate

Atherosclerosis, 1974
Abstract Clofibrate and 3 related drugs (13.437 SU, GP 45.699 and MK 185) have been tested in man with the same protocol and by the same medical team. Comparison of the results of these clinical trials shows that the 4 drugs have common effects with regard to lipidemia, but differ in their action on uricemia and tolerance to antivitamin K: All of ...
V. Beaumont, Buxtorf Jc, Bernard Jacotot, Beaumont Jl   +3 more
openaire   +3 more sources

Syntheses and Biological Evaluation of Alkanediamines as Antioxidant and Hypolipidemic Agents

Bioorganic & Medicinal Chemistry, 2001
A new series of compounds belonging to N,N'- [bis (1-aryl-6-hydroxy-hex-2-ene-1-one-3-yl)-1,n-alkanediamines (2-5a-f) have been synthesized and evaluated for antioxidant and hypolipidemic activities. Amongst all the synthesized compounds, seven compounds namely 2c, 2e, 4c, 5b, 5c, 5e and 5f exhibit potent antioxidant activity. These compounds have also
Raja Roy, Ramesh Chander, Amiya P. Bhaduri, Bhawani S. Joshi, Ashok Kumar Khanna, Sanjay Batra   +5 more
openaire   +3 more sources

Biological Activity of the Hypolipidemic Agent, N2-n-Butylindazolone

Journal of Pharmaceutical Sciences, 1984
Previously, a series of N-substituted indazolone derivatives proved to be effective hypolipidemic agents in rodents. The most effective agent, N2-n-butylindazolone, at 20 mg/kg/d was shown to suppress the levels of cytoplasm acetyl coenzyme A required for cholesterol and fatty acid synthesis as well as sn-glycerol-3-phosphate acyl transferase and ...
Steven D. Wyrick, Iris H. Hall, P. J. Voorstad, W.L. Williams   +3 more
openaire   +3 more sources

Effects of the hepatocarcinogenic peroxisome-proliferating hypolipidemic agents clofibrate and nafenopin on the rat liver cell membrane enzymes gamma-glutamyltranspeptidase and alkaline phosphatase and on the early stages of liver carcinogenesis.

Carcinogenesis, 1984
The effects of the hepatocarcinogenic peroxisome proliferating hypolipidemic agents clofibrate (CF) and nafenopin (NF) on rat liver carcinogenesis initiated by N-2-fluorenylacetamide (FAA) were studied and compared with that of the neoplasm promoter ...
Satoshi Numoto, Kazunori Furukawa, Keizo Furuya, Gary M. Williams   +3 more
semanticscholar   +1 more source

Hypolipidemic agents alter hepatic mitochondrial respiration in vitro

Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology, 1995
The direct effects of three different classes of structurally diverse hypolipidemic agents on respiration were studied in mitochondria isolated from donor Sprague-Dawley rats. Two classes of peroxisome proliferators (i.e. plasticizers and hypolipidemic hormones and drugs) and one class of peroxisome inhibitors (i.e.
David S. Chance, Michael McIntosh
openaire   +3 more sources

Teratogenic action of hypolipidemic agents: an in vitro study with postimplantation rat embryos.

Teratology, 1983
Two hypolipidemic agents known to be embryotoxic and teratogenic in vivo were found also to cause developmental abnormalities when added to the culture serum of rat embryos growing in vitro.
C. Steele, D. New, A. Ashford, G. Copping   +3 more
semanticscholar   +1 more source

5,5-Diaryl-2-thiohydantoins and 5,5-diaryl-N3-substituted-2-thiohydantoins as potential hypolipidemic agents.

Journal of Medicinal Chemistry, 1986
A series of 5,5-diaryl-2-thiohydantoins and 5,5-diaryl-N3-substituted-2-thiohydantoins related to 5,5-diphenyl-2-thiohydantoin (DPTH) were investigated as potential hypolipidemic agents with the goal of increased potency over DPTH itself.
J. Tompkins
semanticscholar   +1 more source

Synthesis of potential hypolipidemic agents. Reaction of substituted phenyl 2,3-epoxypropyl ethers with adenine, uracil, and thymine.

Journal of Medicinal Chemistry, 1978
Three adenine derivatives were found to be active hypolipidemic agents at 10 mg/kg/day. The most active compound was 9-(p-chlorophenoxy-2-hydroxypropyl)adenine (5).
W. S. Dimenna, C. Piantadosi, R. G. Lamb
semanticscholar   +1 more source

[Aryloxy- and arylthioalkylamine hypolipidemic agents].

Il Farmaco; edizione scientifica, 1983
Aryloxy and arylthioalkylamines related respectively to clofibrate and 2-(3,5-di-t-butyl-4-hydroxyphenylthio)hexanoic acid, a derivative of an active probucol metabolite, were prepared and pharmacologically screened as hypolipidemic substances. Some of them showed interesting antilipemic activity but also, unfortunately, high acute toxicity.
DURANTI E, BONIFAZI, PAOLA, SALVATORI A, BALSAMINI, CESARINO, PERUZZI G, CANTONI, ORAZIO   +5 more
openaire   +2 more sources

FDA considerations regarding new hypolipidemic agents

Lipids, 1977
AbstractFood and Drug Administration policy being considered for new marketed hypolipidemic agents includes: long‐term safety to be demonstrated in postmarketing studies; evidence of clinical effectiveness to be demonstrated within a specified time period. Effectiveness is to be judged by one or more of the following: reduction in xanthomata, reduction
openaire   +3 more sources